Evidence map›Paper›PMID 40667322›Full record

ArticlebioRxiv : the preprint server for biology2025

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.

Ed J Griffen, Daren Fearon, Briana L McGovern, Lizbe Koekemoer, Blake H Balcomb, Tamas Szommer, Gwendolyn Fate, Ralph P Robinson, Bruce A Lefker, Shirly Duberstein and 25 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Ed J GriffenMedChemica Consultancy Ltd, Motorworks, Chestergate, Macclesfield, SK11 6GU, UK.
Daren FearonDiamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.
Briana L McGovernDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lizbe KoekemoerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Blake H BalcombDiamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.
Tamas SzommerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Gwendolyn FateThames Pharma Partners LLC, Mystic, Connecticut, USA.
Ralph P RobinsonThames Pharma Partners LLC, Mystic, Connecticut, USA.
Bruce A LefkerThames Pharma Partners LLC, Mystic, Connecticut, USA.
Shirly DubersteinG-INCPM, Weizmann Institute of Science, Rechovot, Israel.
Noa LahavG-INCPM, Weizmann Institute of Science, Rechovot, Israel.
COVID Moonshot Consortium
Stephanie BraillardDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Laura VangeelVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Manon LaporteVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Fabienne Burgat CharvillonDrugs for Neglected Diseases initiative, Geneva, Switzerland.
A Kenneth MacLeodDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.
Andrew WellsCharnwood Technical Consulting, UK.
Pauline GarnerApconiX, Mereside, Alderley Park, Cheshire, UK.
Richard KnightApconiX, Mereside, Alderley Park, Cheshire, UK.
Paul ReesCompass Business Partners Ltd, Gerrards Cross, UK.
Anthony SimonDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Dirk JochmansVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0002-9265-6028
Johan NeytsVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Kevin D ReadDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.
Haim BarrG-INCPM, Weizmann Institute of Science, Rechovot, Israel.
Matthew RobinsonPostEra Inc., Cambridge, MA 02142, USA.
Alpha LeePostEra Inc., Cambridge, MA 02142, USA.
Nir LondonDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
John ChoderaProgram in Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-0542-119X
Frank von DelftCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Kris M WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ben PerryDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Peter SjöDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Annette von DelftCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-7699-8140

Funding

Strengthening the ISMMS research and response capabilities for pathogens of pandemic potentialG20AI174733 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBRECHT, RANDY A. · 2022 to 2022
$2.3M
NIAID NIH HHS G20 AI174733Wellcome Trust
6 · The paper itself

Abstract

The 2020 SARS-CoV-2 coronavirus pandemic highlighted the urgent need for novel small molecule antiviral drugs. (S)-

Identifiers

PMID40667322
PMCPMC12262575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.